Introduction {#jcmm12813-sec-0001}
============

Recently, it has been increasingly recognized that primary disorder of kidney will induce or worsen pathological injuries in heart, which in turn can lead to accelerated organ dysfunction in both systems. This phenomenon has been defined as chronic renocardiac syndrome or type 4 cardiorenal syndrome (CRS) [1](#jcmm12813-bib-0001){ref-type="ref"}. Clinical studies demonstrated that patients with primary chronic kidney disease (CKD) show higher incidence of cardiovascular diseases (CVD) and a 10‐ to 20‐fold increased risk of cardiac death compared with that of the general population [2](#jcmm12813-bib-0002){ref-type="ref"}, [3](#jcmm12813-bib-0003){ref-type="ref"}. However, there are still no effective strategies for treatment of CRS for now. Thus, it is urgent to identify underlying mechanisms of CRS progression for developing novel therapy.

Although the exact pathophysiology mechanisms underlying this bidirectional cardiorenal crosstalk are not fully elucidated yet, traditional risks in CKD such as humoural and haemodynamic disturbance and activation of renin--angiotensin--aldosterone system and sympathetic nerve system (SNS) may contribute to the pathogenesis of CVD [4](#jcmm12813-bib-0004){ref-type="ref"}, [5](#jcmm12813-bib-0005){ref-type="ref"}. Recently, it has been suggested that abnormalities in bone‐mineral axis and deficiency of erythropoietin (EPO) or klotho may directly aggravate cardiac hypertrophy and participate in the pathogenesis of worsening of renal function and cardiovascular complication [6](#jcmm12813-bib-0006){ref-type="ref"}, [7](#jcmm12813-bib-0007){ref-type="ref"}. Therefore, special emphasis should be placed on the endocrine function of kidney [8](#jcmm12813-bib-0008){ref-type="ref"}. The reduction or loss of EPO, calcitriol or klotho and yet‐to‐be known kidney‐derived hormones or cytokines as a result of renal dysfunction may be potential mechanisms of CRS [9](#jcmm12813-bib-0009){ref-type="ref"}.

Renalase, a recently discovered flavoprotein from kidney, can regulate blood pressure by degrading circulatory catecholamines [10](#jcmm12813-bib-0010){ref-type="ref"}. Our previous reports demonstrated that renalase is up‐regulated during various stresses including hypoxia, ischaemia/reperfusion and oxidative stress [11](#jcmm12813-bib-0011){ref-type="ref"}, [12](#jcmm12813-bib-0012){ref-type="ref"}, [13](#jcmm12813-bib-0013){ref-type="ref"}. Administration of recombinant renalase protects against AKI, contrast‐induced nephropathy and cardiac ischaemia/reperfusion injury [12](#jcmm12813-bib-0012){ref-type="ref"}, [13](#jcmm12813-bib-0013){ref-type="ref"}, [14](#jcmm12813-bib-0014){ref-type="ref"}, [15](#jcmm12813-bib-0015){ref-type="ref"}. Clinical studies showed that renalase deficiency or single‐nucleotide polymorphisms are associated with essential hypertension, cardiac hypertrophy, stroke and diabetes [16](#jcmm12813-bib-0016){ref-type="ref"}, [17](#jcmm12813-bib-0017){ref-type="ref"}, [18](#jcmm12813-bib-0018){ref-type="ref"}, [19](#jcmm12813-bib-0019){ref-type="ref"}, [20](#jcmm12813-bib-0020){ref-type="ref"}. Recently, mounting evidence suggested that renalase exerts its cytoprotective effects by interacting with its plasma membrane receptor other than metabolizing catecholamines [21](#jcmm12813-bib-0021){ref-type="ref"}, [22](#jcmm12813-bib-0022){ref-type="ref"}, [23](#jcmm12813-bib-0023){ref-type="ref"}. Thus, renalase may serve as a cytokine that regulates kidney function in autocrine or paracrine manner [24](#jcmm12813-bib-0024){ref-type="ref"}. Nevertheless, whether renalase supplementation could prevent the progression of renal injury and occurrence of remote organ injury in CKD and its mechanisms still remain unknown.

Western blot analyses demonstrated that plasma renalase concentration in CKD patients is substantially decreased in comparison to healthy population [10](#jcmm12813-bib-0010){ref-type="ref"}. However, several clinical studies using ELISA reported opposite results [25](#jcmm12813-bib-0025){ref-type="ref"}, [26](#jcmm12813-bib-0026){ref-type="ref"}. These opposite results may be inaccurate because of a not validated antibody used in the commercially kit which would non‐specifically recognize renalase breakdown products or unrelated epitopes [27](#jcmm12813-bib-0027){ref-type="ref"}. Consistently, renalase deficiency is also present in rats subjected to subtotal nephrectomy [28](#jcmm12813-bib-0028){ref-type="ref"}. Thus, it is reasonable to speculate that renalase may be also a crucial kidney‐derived modulator for CRS progression. In present study, we examined the effects of renalase supplementation by an adenovirus delivery on the progression of type 4 CRS in a rat subtotal nephrectomy model. Furthermore, the potential mechanisms mediating renalase\'s protective effects were also investigated.

Material and methods {#jcmm12813-sec-0002}
====================

Construction of adenovirus vectors {#jcmm12813-sec-0003}
----------------------------------

The replication‐deficient recombinant adenovirus vectors expressing the rat renalase mRNA sequence or β‐galactosidase (β‐gal) were generated respectively, under the control of the cytomegalovirus enhancer/promoter. These adenoviruses were amplified in HEK‐293A cells and purified by CsCl ultracentrifugation and store at −80°C in Hanks\' balanced salt solution (HBSS) with a concentration of 1.0 × 10^10^ plaque formation unit (PFU)/ml.

Animal {#jcmm12813-sec-0004}
------

All the animal experiments were approved by the Animal Care and Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital. Male Sprague--Dawley rats were provided by Shanghai Science Academy animal center. All the rats were housed in a 12/12 hrs light/dark cycle with free access to water and fed with standard rat chow.

Rat model of CKD and experimental protocols {#jcmm12813-sec-0005}
-------------------------------------------

Male Sprague--Dawley rats weighing 200--250 g, after 7‐day adaption period, were randomly allocated to either sham‐operated group or 5/6 subtotal nephrectomy group. The animals were anaesthetized by intraperitoneally injection of sodium pentobarbital (50 mg/kg) and two‐stage subtotal nephrectomy was performed as previously described [29](#jcmm12813-bib-0029){ref-type="ref"}. Briefly, the upper and lower poles of the left kidney were resected and bleeding was controlled. One week later, the right kidney was removed after ligation of the renal blood vessels and the ureter. The sham‐operated rats underwent the same procedures, but only the envelope capsule was removed.

Two weeks after surgery, the rats were further randomly divided into following groups: (*i*) sham‐operated treated with tail vein injection of 1.2 ml HBSS (sham, *n* = 10); (*ii*) subtotal nephrectomy treated with tail vein injection of 1.2 × 10^10^ PFU control adenovirus (STNx+Ad‐β‐gal, *n* = 10); (*iii*) subtotal nephrectomy treated with tail vein injection of 1.2 × 10^10^ PFU adenovirus‐renalase (STNx+Ad‐renalase, *n* = 10). The effect of renalase gene delivery on CRS was assessed 4 weeks after adenovirus injection (corresponding to Week 6 of CKD). At the end of the experiment, all the rats were kept 24 hrs in metabolic cages for urine collection and echocardiography was also examined during the last week. Then all the animals were killed and blood as well as kidney and heart tissues were harvested for analyses.

Renal function assessment {#jcmm12813-sec-0006}
-------------------------

Blood samples were collected from abdominal aorta and centrifuged to obtain plasma and then separated into aliquots and stored at −20°C. Blood urea nitrogen (BUN) and urinary creatinine and proteinuria were measured by commercial kit (Nanjingjiancheng, Nanjing, Jiangsu, China). The ratio of left kidney weight to bodyweight (bw) was also calculated to evaluate renal dysfunction. Plasma norepinephrine concentration was evaluated by ELISA kit (LDN, Nordhorn, Germany).

Systolic blood pressure measurement {#jcmm12813-sec-0007}
-----------------------------------

Systolic blood pressure (SBP) was measured prior to adenovirus injection and once a week after gene delivery by a tail‐cuff method, using CODA blood pressure systems (Kent Scientific, Torrington, CT, USA). Prior to the actual experiments, the conscious animals were training for three consecutive days to become accustomed to the procedure. For each animal, at least 15 measurements were recorded to calculate a mean blood pressure and heart rate.

Cardiac functional assessment {#jcmm12813-sec-0008}
-----------------------------

Transthoracic echocardiography was performed at the end‐point using a VeVo770 High Resolution Imaging System (Visual Sonics Inc., Toronto, ON, Canada) with 17.5 MHz transducer as previously described [30](#jcmm12813-bib-0030){ref-type="ref"}. M‐mode and 2D parasternal short‐axis views were analysed in the anaesthetized rats by trained echocardiographers who were blinded to the treatments.

Before being killed, all the rats underwent LV (left ventricular) catheterization to assess haemodynamics changes as previously described [31](#jcmm12813-bib-0031){ref-type="ref"}. The transducer was attached to RM6240BD multichannel biotic signal collection and analysis instrument (Taimeng, Chengdu, China) to determine cardiac function. LV systolic pressure, LV end‐diastolic pressure (LVEDP) and the maximal rate of pressure rise (dP/dt~max~) and fall (dP/dt~min~) were recorded respectively.

Heart weight (HW) index were analysed among the three groups. The hearts were rapidly excised, cleaned and weighed. The left ventricles were separated and weighed. The ratios of the whole HW to bw, the ratios of the LV weight (LW) to bw were calculate to evaluate cardiac hypertrophy.

Histology analysis {#jcmm12813-sec-0009}
------------------

All the tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Tissue sections (4--6 μm) were stained with haematoxylin and eosin, Masson trichrome solution or Sirus Red to assess histological injury and fibrosis.

A semi‐quantitative score was used to determine the severity of glomerulosclerosis and tubulointerstitial injury as described previously [32](#jcmm12813-bib-0032){ref-type="ref"}, [33](#jcmm12813-bib-0033){ref-type="ref"}. Glomerular area was measured as described previously [34](#jcmm12813-bib-0034){ref-type="ref"}. All evaluation was performed by an observer who was blind to the experimental protocol. To evaluate the degree of fibrosis, 10 non‐overlapping fields of each section were randomly chosen. Cross‐section area of cardiomyocytes was calculated from the average of 50 cardiomyocytes per section as described previously [35](#jcmm12813-bib-0035){ref-type="ref"}.

For immunohistochemistry, kidney sections were stained with antirat monoclonal antibodies against CD68 (Sigma‐Aldrich, St. Louis, MO, USA), CD86, CD163 and renalase (both from Abcam, Cambridge, MA, USA) as previously described [36](#jcmm12813-bib-0036){ref-type="ref"}. All the measurements were calculated by ImagePro Plus Systems.

Quantitative real‐time PCR {#jcmm12813-sec-0010}
--------------------------

Total RNA were extracted from the renal cortex or LV tissue using Trizol (Invitrogen, Carlsbad, CA, USA) and was reverse transcribed into cDNA with M‐MLV Reverse Transcriptase (Promega, Madison, WI, USA). Real‐time PCR was performed with SYBE Green PCR master Mix (Tarkara, Dalian, China) using StepOnePlus PCR Systems (Applied Biosystems, Foster City, CA, USA) according to the manufacturer\'s protocol. Quantitation was normalized to internal control GAPDH and 2^−ΔΔCT^ method was used to determine relative gene expression levels. All the primer pairs are seen in Table S1.

Western blot analysis {#jcmm12813-sec-0011}
---------------------

Total protein was prepared from frozen tissues by homogenization. Protein concentrations were determined by BCA assay (Beyotime, Suzhou, Jiangsu, China) and protein samples were separated by 10--12% SDS‐PAGE and then transferred to polyvinylidene difluoride membrane. The membranes were blocked with 5% non‐fat dried milk and then incubated with primary antibodies against matrix metalloproteinase 1 (MMP‐1), tissue inhibitor of metalloproteinase‐1 (TIMP‐1), renalase (Abcam), phospho‐ERK‐1/2, total ERK‐1/2, phospho‐p38, total p38 (Cell Signaling Technology, Danvers, MA, USA). Horseradish peroxidase‐conjugated secondary antibodies (Beyotime) were used and visualized by Image Quant LAS 4000 Mini System (GE Healthcare, Pittsburgh, PA, USA). The bands were analysed using Image J software and GAPDH or tubulin (Proteintech, Chicago, IL, USA) was used as internal control.

Statistical analyses {#jcmm12813-sec-0012}
--------------------

SPSS software 19.0 (IBM, Armonk, NY, USA) was used for all the statistical analyses. All the values are expressed as mean ± S.E.M. One‐way [anova]{.smallcaps} followed by a with Tukey\'s Multiple Comparison Test was used to compare parametric data while Kruskal--Wallis test followed by the Mann--Whitney *U*‐test was used for non‐parametric data comparison. A value of *P* \< 0.05 were considered statistically significant.

Results {#jcmm12813-sec-0013}
=======

Adenovirus‐mediated gene delivery efficacy {#jcmm12813-sec-0014}
------------------------------------------

As shown in Figure S1, subtotal nephrectomy resulted in dramatic decrease in renalase expression both in the plasma, remnant kidney and heart compared with sham group. Renalase gene delivery restored renalase expression nearly to normal levels in circulation, kidney and heart according to Western blot and PCR results in STNx rats (Fig. S1). Consistently, immunohistochemistry analysis also showed adenovirus‐renalase effectively increase the percentage of renalase‐positive cells in kidney compared with Ad‐β‐gal‐treated STNx rats (Fig. S2).

Renalase gene delivery ameliorated renal dysfunction in STNx rats {#jcmm12813-sec-0015}
-----------------------------------------------------------------

Compared to sham group, STNx rats exhibited significant renal dysfunction characterized by increased plasma BUN, urine 24 hrs total protein levels, and decreased creatinine clearance as shown in Table [1](#jcmm12813-tbl-0001){ref-type="table-wrap"}. After 4 weeks of treatment, systemic delivery of renalase significantly decreased plasma BUN and proteinuria in STNx rats. Kidney weight/bw was also lower in Ad‐renalase‐treated group than Ad‐β‐gal‐treated group (Table [1](#jcmm12813-tbl-0001){ref-type="table-wrap"}). In addition, Ad‐renalase delivery attenuated creatinine clearance decline in STNx rats. Furthermore, plasma norepinephrine level in Ad‐renalase‐treated STNx rats was also significantly lower than Ad‐β‐gal‐treated STNx rats (Table [1](#jcmm12813-tbl-0001){ref-type="table-wrap"}); suggesting renalase may participate in the metabolism of catecholamines.

###### 

General characteristics of rats and renal function assessments 6 weeks after surgery

                                   Sham           STNx+Ad‐β‐gal                                             STNx+Ad‐renalase
  -------------------------------- -------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Bodyweight (g)                   485 ± 17       410 ± 19[\*](#jcmm12813-note-0001){ref-type="fn"}         425 ± 15
  Left kidney weight/bw (mg/g)     5.31 ± 0.17    4.5 ± 0.48[\*\*](#jcmm12813-note-0001){ref-type="fn"}     4.1 ± 0.39[\*\*](#jcmm12813-note-0001){ref-type="fn"} ^,^ [\#](#jcmm12813-note-0001){ref-type="fn"}
  Serum urea nitrogen              5.62 ± 0.86    17.23 ± 1.21[\*\*](#jcmm12813-note-0001){ref-type="fn"}   13.59 ± 0.99[\*](#jcmm12813-note-0001){ref-type="fn"} ^,^ [\#](#jcmm12813-note-0001){ref-type="fn"}
  Proteinuria (mg/24 hrs)          12.08 ± 1.29   134 ± 9.76[\*\*\*](#jcmm12813-note-0001){ref-type="fn"}   59.90 ± 5.79[\*\*\*](#jcmm12813-note-0001){ref-type="fn"} ^,^ [\#\#](#jcmm12813-note-0001){ref-type="fn"}, [\#](#jcmm12813-note-0001){ref-type="fn"}
  Creatinine clearance (ml/min.)   1.56 ± 0.18    0.87 ± 0.20[\*\*](#jcmm12813-note-0001){ref-type="fn"}    1.13 ± 0.2[\*](#jcmm12813-note-0001){ref-type="fn"} ^,^ [\#](#jcmm12813-note-0001){ref-type="fn"}
  Norepinephrine (pg/ml)           438 ± 49       1280 ± 81[\*](#jcmm12813-note-0001){ref-type="fn"}        667 ± 78[\#](#jcmm12813-note-0001){ref-type="fn"}

*\*P* \< 0.05 *versus* sham; ^\#^ *P* \< 0.05 *versus* STNx+Ad‐β‐gal; *\*\*P* \< 0.01 *versus* sham; ^\#\#^ *P* \< 0.01 *versus* STNx+Ad‐β‐gal; *\*\*\*P* \< 0.001 *versus* sham; ^\#\#\#^ *P* \< 0.001 *versu*s STNx+Ad‐β‐gal.

All values are presented as means ± S.E.M. (*n* = 10).

STNx: subtotal nephrectomy; bw: bodyweight.
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Renalase supplementation attenuated renal pathological injury {#jcmm12813-sec-0016}
-------------------------------------------------------------

Kidney sections from STNx rats revealed a remarkable glomerular hypertrophy and tubular enlargement (Fig. [1](#jcmm12813-fig-0001){ref-type="fig"}A). Ad‐renalase treatment significantly decreased glomerular area (Fig. [1](#jcmm12813-fig-0001){ref-type="fig"}G) and ameliorated glomerularsclerosis and tubulointerstitial injury after subtotal nephrectomy as assessed by pathological score (Fig. [1](#jcmm12813-fig-0001){ref-type="fig"}E and F). To evaluate the extent of interstitial fibrosis, kidney tissues were stained with Masson and Sirus Red. Results showed that renal interstitial fibrosis in Ad‐renalase‐treated rats was less severe than that in Ad‐β‐gal‐treated STNx rats as shown in Figure [1](#jcmm12813-fig-0001){ref-type="fig"}B--D. Consistent with the histological data, mRNA levels of fibrosis markers, including collagen I, collagen III and transforming growth factor (TGF)‐β1 were significantly higher in the remnant kidneys of Ad‐β‐gal‐treated STNx rats than in those of sham rats; and Ad‐renalase treatment significantly decreased mRNA expression of these fibrosis markers (Fig. [3](#jcmm12813-fig-0003){ref-type="fig"}A).

![Renalase gene delivery attenuated renal injury 6 weeks after subtotal nephrectomy. (**A**) Histologic examination of renal injury by HE staining for sham‐operated, Ad‐β‐gal ‐treated STNx rats and Ad‐renalase‐treated STNx rats, magnification, ×200. (**B**) Assessment of interstitial fibrosis by Masson staining, magnification, ×100. (**C**) Representative picture of Sirus Red staining in standard light, magnification, ×100. (**D**) Representative picture of Sirus Red staining in polarized light, magnification, ×100. (**E**) Semi‐quantitative analysis of glomerular injury. (**F**) Semi‐quantitative analysis of tubulointerstitial injury. (**G**) Quantification of glomerular cross‐section area. (**H**) Quantitative analysis of interstitial fibrosis by Masson. (**I**) Quantitative analysis of interstitial fibrosis by Sirus Red. All values are presented as means ± S.E.M. (*n* = 10). \**P* \< 0.05 versus sham; \*\*\**P* \< 0.001 *versus* sham; \#*P* \< 0.05 *versus* STNx+Ad‐β‐gal; \#\#*P* \< 0.01 *versus* STNx+Ad+β‐gal.](JCMM-20-1106-g001){#jcmm12813-fig-0001}

Renalase inhibited inflammation and oxidative stress in the remnant kidney {#jcmm12813-sec-0017}
--------------------------------------------------------------------------

To explore whether renalase was involved in macrophage infiltration, activation and polarization, we examined renal infiltration of total macrophage (CD68), M1‐like (CD86) and M2‐like macrophage (CD163). Immunohistochemistry analysis showed that CKD rats displayed increased all subtypes of macrophage infiltration and enhanced M1 polarization. Ad‐renalase administration significantly diminished total macrophage infiltration numbers especially M1 numbers than Ad‐β‐gal‐treated rats after subtotal nephrectomy (Fig. [2](#jcmm12813-fig-0002){ref-type="fig"}). In addition, Ad‐renalase‐treated rats exhibited slightly more M2 infiltration than Ad‐β‐gal‐treated rats.

![Renal macrophage M1/M2 phenotype was altered by renalase supplementation. (**A**) Representative photographs of immune staining for CD68, magnification, ×400. (**B**) Representative photographs of CD86 immunostaining, magnification, ×400. (**C**) Representative photographs of CD163 immunostaining, magnification, ×400. Quantitative analysis of CD68 (**D**), CD86 (**E**) and CD163 (**F**) positive macrophage numbers per field. All values are presented as means ± S.E.M. (*n* = 10). \**P* \< 0.05 *versus* sham; ^\#^ *P* \< 0.05 *versus* STNx+Ad‐β‐gal.](JCMM-20-1106-g002){#jcmm12813-fig-0002}

To determine the effects of renalase supplementation on inflammation and oxidative stress, mRNA levels of pro‐inflammatory cytokines and NADPH oxidase components were also measured by real‐time PCR. Nephrectomized rats showed higher expression levels of pro‐inflammatory cytokines, including tumour necrosis factor (TNF)‐α, interleukin (IL)‐6, monocyte chemotactic protein (MCP)‐1 (Fig. [3](#jcmm12813-fig-0003){ref-type="fig"}B) and NADPH oxidase components, including gp91^phox^, p47^phox^ and p67^phox^ compared with sham (Fig. [3](#jcmm12813-fig-0003){ref-type="fig"}C); and Ad‐renalase treatment decreased the expression of pro‐inflammatory cytokines and NADPH oxidase components. Taking together, these findings indicated renalase supplementation might protect renal injury after renal ablation *via* inhibiting inflammation activation and oxidative stress in remnant kidney.

![Ad‐renalase‐treated rats exhibited decreased mRNA expression of fibrosis markers, pro‐inflammatory cytokines and NADPH oxidative stress components in the kidney. (**A**) Relative mRNA expression collagen I, collagen III and TGF‐β1. (**B**) Relative mRNA expression of TNF‐α, IL‐6 and MCP‐1. (**C**) Relative mRNA expression of gp91^phox^, P47^phox^ and P67^phox^. All values are expressed as mean ± S.E.M. (*n* = 10). \**P* \< 0.05 *versus* sham; ^\#^ *P* \< 0.05 *versus* STNx+Ad‐β‐gal; \*\**P* \< 0.01 *versus* sham.](JCMM-20-1106-g003){#jcmm12813-fig-0003}

Effects of renalase on systolic blood pressure {#jcmm12813-sec-0018}
----------------------------------------------

As shown in Figure [4](#jcmm12813-fig-0004){ref-type="fig"}, SBP in STNx rats gradually increased during the observation compared with the sham group and Ad‐renalase delivery significantly decreased SBP in STNx rats compared with Ad‐β‐gal‐treated rats.

![Systolic blood pressure of sham‐operated, Ad‐β‐gal‐treated STNx rats and Ad‐renalase‐treated STNx rats. Systolic blood pressure values are expressed as mean ± S.E.M. (*n* = 10). \**P* \< 0.05 *versus* sham; ^\#^ *P* \< 0.05 *versus* STNx+Ad‐β‐gal; \*\**P* \< 0.01 *versus* sham; ^\#\#^ *P* \< 0.01 *versus* STNx+Ad‐β‐gal; \*\*\**P* \< 0.001 *versus* sham; ^\#\#\#^ *P* \< 0.001 *versus* STNx+Ad‐β‐gal.](JCMM-20-1106-g004){#jcmm12813-fig-0004}

Renalase supplementation prevented cardiac remodelling in STNx rats {#jcmm12813-sec-0019}
-------------------------------------------------------------------

The HW/bw and LV weight/bw were significantly higher in STNx rats than the sham and significantly lower in Ad‐renalase‐treated rats than the Ad‐β‐gal‐treated rats (Table [2](#jcmm12813-tbl-0002){ref-type="table-wrap"}). Concomitant alterations were found in echocardiography (Table [2](#jcmm12813-tbl-0002){ref-type="table-wrap"} and Fig. S3), 4 weeks of treatment with Ad‐renalase significantly decreased LVPWd, LVAWd and increased LVIDs and LVIDs (Table [2](#jcmm12813-tbl-0002){ref-type="table-wrap"}). However, there was no difference in FS and EF among the three groups.

###### 

Cardiac function assessment 6 weeks after surgery

                              Sham           STNx+Ad‐β‐gal                                              STNx+Ad‐renalase
  --------------------------- -------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  HR                          371 ± 31       410 + 13                                                   402 ± 19
  HW/bw (mg/g)                2.35 ± 0.17    3.9 ± 0.25[\*\*\*](#jcmm12813-note-0004){ref-type="fn"}    3.68 ± 0.21[\*\*](#jcmm12813-note-0004){ref-type="fn"} ^,^ [\#](#jcmm12813-note-0004){ref-type="fn"}
  LW/HW (mg/g)                4.1 ± 0.36     6.1 ± 0.53[\*\*\*](#jcmm12813-note-0004){ref-type="fn"}    5.6 ± 0.49[\*\*](#jcmm12813-note-0004){ref-type="fn"} ^,^ [\#](#jcmm12813-note-0004){ref-type="fn"}
  Echocardiography                                                                                      
  LVPWd (mm)                  2.01 ± 0.08    2.88 ± 0.16[\*\*\*](#jcmm12813-note-0004){ref-type="fn"}   1.99 ± 0.13[\#\#\#](#jcmm12813-note-0004){ref-type="fn"}
  LVPWs (mm)                  3.22 ± 0.16    4.24 ± 0.08[\*\*\*](#jcmm12813-note-0004){ref-type="fn"}   3.60 ± 0.15[\#\#](#jcmm12813-note-0004){ref-type="fn"}
  LVAWd (mm)                  1.81 ± 0.07    2.43 ± 0.01[\*\*\*](#jcmm12813-note-0004){ref-type="fn"}   1.91 ± 0.08[\#\#](#jcmm12813-note-0004){ref-type="fn"}
  LVAWs (mm)                  3.10 ± 0.15    4.22 ± 0.13[\*\*\*](#jcmm12813-note-0004){ref-type="fn"}   3.64 ± 0.13[\*](#jcmm12813-note-0004){ref-type="fn"} ^,^ [\#](#jcmm12813-note-0004){ref-type="fn"}
  LVIDd (mm)                  7.05 ± 0.27    5.57 ± 0.20[\*](#jcmm12813-note-0004){ref-type="fn"}       7.05 ± 0.31[\#\#](#jcmm12813-note-0004){ref-type="fn"}
  LVIDs (mm)                  3.32 ± 0.40    1.58 ± 0.19[\*\*](#jcmm12813-note-0004){ref-type="fn"}     2.66 ± 0.29[\#\#](#jcmm12813-note-0004){ref-type="fn"}
  Fractional shortening (%)   52.02 ± 3.57   71.34 ± 3.26                                               60.59 ± 3.64
  EF (%)                      94.35 ± 1.6    80.81 ± 3.39                                               87.72 ± 2.7
  Cardiac catheterization                                                                               
  LVEDP (mmHg)                2.3 ± 0.49     6.5 ± 0.56[\*\*](#jcmm12813-note-0004){ref-type="fn"}      4.5 ± 0.40[\*](#jcmm12813-note-0004){ref-type="fn"} ^,^ [\#](#jcmm12813-note-0004){ref-type="fn"}
  LVESP (mmHg)                70.45 ± 5.98   69.43 ± 7.89                                               80.32 ± 5.76
  +dP/dt~max~ (mmHg/sec.)     4954 ± 389     5130 ± 447                                                 4986 ± 450
  −dP/dt~min~ (mmHg/sec.)     −4823 ± 430    −3960 ± 536                                                −4423 ± 378

*\*P* \< 0.05 *versus* sham; ^\#^ *P* \< 0.05 *versus* STNx+Ad‐β‐gal; *\*\*P* \< 0.01 *versus* sham; ^\#\#^ *P* \< 0.01 *versus* STNx+Ad‐β‐gal; *\*\*\*P* \< 0.001 *versus* sham; ^\#\#\#^ *P* \< 0.001 *versus* STNx+Ad‐β‐gal.

All values are presented as means ± S.E.M. (*n* = 8).

LVPWd: LV end‐diastolic posterior wall thickness; LVPWs: LV end‐systole posterior wall thickness; LVAWd: LV end‐diastolic anterior wall thickness; LVAWs: LV end‐systole anterior wall thickness; LVIDd: LV internal diastolic diameter; LVIDs: LV internal systolic diameter; dP/dtmax: rate of LV pressure rise; −dP/t~min~: rate of LV pressure fall; LVEDP: LV end‐diastolic pressure; LVESP: LV end‐systolic pressure.
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Histological sections of hearts demonstrated that subtotal nephrectomy led to elevated cross‐section area of cardiomyocytes and Ad‐renalase delivery ameliorated cardiac cardiomyocytes hypertrophy in STNx rats (Fig. [5](#jcmm12813-fig-0005){ref-type="fig"}A and C). Cardiac fibrosis assessment, determined by Masson staining, showed that STNx rats had more matrix deposition than sham; and lesser cardiac interstitial fibrosis was observed in the Ad‐renalase‐treated rats compared with Ad‐β‐gal‐treated STNx rats (Fig. [5](#jcmm12813-fig-0005){ref-type="fig"}B and D). In addition, Western blot showed that expression of MMP‐1 was significantly lower in Ad‐β‐gal‐treated rats than sham and significantly higher in Ad‐renalase‐treated rats than Ad‐β‐gal‐treated rats. Meanwhile, the expression of TIMP‐1 and TGF‐β was significantly higher in Ad‐β‐gal‐treated rats than sham and significantly lower in Ad‐renalase‐treated rats compared with Ad‐β‐gal‐treated rats (Fig. [6](#jcmm12813-fig-0006){ref-type="fig"}A--C).

![Systemic delivery of renalase ameliorated cardiomyocytes hypertrophy and cardiac fibrosis. (**A**) Representative photographs of HE of the heart sections from three groups at week 6, magnification, ×400. (**B**) Representative photographs of Masson staining for cardiac fibrosis, magnification, ×200. (**C**) Quantitative analysis of cross‐section area of cardiomyocytes. (**D**) Quantitative evaluation of cardiac fibrosis. All values are presented as means ± S.E.M. (*n* = 10). \**P* \< 0.05 *versus* sham; ^\#^ *P* \< 0.05 *versus* STNx+Ad‐β‐gal.](JCMM-20-1106-g005){#jcmm12813-fig-0005}

![Ad‐renalase treatment normalized cardiac expression of pro‐fibrotic markers and phosphorylated ERK‐1/2 in CKD rats. Representative Western blot and quantification of TGF‐β (**A**), MMP‐1 (**B**), TIMP‐1 (**C**) and phosphorylated ERK‐1/2 (**D**) expression in left ventricle from three groups at week 6. All values are presented as means ± S.E.M. (*n* = 10). \**P* \< 0.05 *versus* sham; \*\**P* \< 0.01 *versus* sham; ^\#^ *P* \< 0.05 *versus* STNx+Ad‐β‐gal.](JCMM-20-1106-g006){#jcmm12813-fig-0006}

Deactivation of mitogen‐activated protein kinases after treatment with Ad‐renalase {#jcmm12813-sec-0020}
----------------------------------------------------------------------------------

The phosphorylated of ERK‐1/2 (p‐ERK‐1/2) in heart (Fig. [6](#jcmm12813-fig-0006){ref-type="fig"}D) and kidney (Fig. [7](#jcmm12813-fig-0007){ref-type="fig"}A) was both significantly increased in STNx rats. And Ad‐renalase treatment significantly decreased the phosphorylation of ERK‐1/2 compared with Ad‐β‐gal‐treated rats. However, there is no significant difference in the expression of phosphorylated p38 (p‐p38) among the three groups (Fig. [7](#jcmm12813-fig-0007){ref-type="fig"}B).

![Ad‐renalase treatment suppressed ERK‐1/2 phosphorylation in the remnant kidney. Representative Western blots of phosphorylated ERK‐1/2 (**A**) and phosphorylated p38 (**B**) in kidney. Values are presented as means ± S.E.M. (*n* = 10). \**P* \< 0.05 *versus* sham; *\*\*P* \< 0.01 *versus* sham; ^\#\#^ *P* \< 0.01 *versus* STNx+Ad‐β‐gal; NS, no statistically significant.](JCMM-20-1106-g007){#jcmm12813-fig-0007}

Discussion {#jcmm12813-sec-0021}
==========

In a pathological circumstance such as CRS, bidirectional heart--kidney interactions could lead to a vicious cycle which must be prevented. It has been identified that several hormones or cytokines secreted by kidney or heart have beneficial effect on other organ and may represent as potential therapeutic targets. For instance, EPO prevented cardiac remodelling in nephrectomized rats beyond haematopoiesis and independent of kidney function [37](#jcmm12813-bib-0037){ref-type="ref"}, [38](#jcmm12813-bib-0038){ref-type="ref"}. Conversely, overexpression of hormones such as brain natriuretic peptide [29](#jcmm12813-bib-0029){ref-type="ref"} and Follistatin‐like 1 (Fstl‐1) secreted by heart, attenuated renal fibrosis and cardiac‐specific Fstl‐1 knockout mice exhibited exacerbation of renal injury after subtotal nephrectomy [39](#jcmm12813-bib-0039){ref-type="ref"}. In the present study, we confirmed the beneficial effects of renalase supplementation on functional and histological alterations of kidney and heart and investigated the underlying mechanism in a rat model with progressive renal injury. We demonstrated that systemic delivery of renalase, a kidney‐derived protein, attenuated both renal and cardiac fibrosis, improved renal function and prevented cardiac remodelling 6 weeks after renal ablation through its anti‐inflammatory and anti‐oxidant effects and inhibition of ERK pathway, indicating that renalase may play a crucial role in the interaction between kidney and heart.

Renalase is a novel protein secreted by kidney and firstly reported to be a catecholamine‐metabolizing enzyme. Our previous reports demonstrated that only kidney tubular epithelial cells could secrete renalase *in vitro*, thus tubular epithelial cells may be the primary source of circulation renalase [40](#jcmm12813-bib-0040){ref-type="ref"}. Reduction of plasma and kidney renalase levels may contribute to elevated circulating catecholamines and consequent SNS activation in CKD rats. In agreement with Baraka\'s study [41](#jcmm12813-bib-0041){ref-type="ref"}, we found that renalase supplementation indeed decreased the circulation norepinephrine level, SBP and attenuated cardiac hypertrophy. More importantly, rats with renalase administration also showed improvement of albuminuria, glomerulosclerosis, tubular dilation and interstitial fibrosis after renal ablation, which was not observed in previous report [41](#jcmm12813-bib-0041){ref-type="ref"}. This difference may be caused by distinct methods of renalase supplementation. Recombinant protein subcutaneously injection is susceptible to be degraded while adenovirus can broadly infect various cells and leads to effective gene overexpression, is thought to be a more appropriate tool for long‐term experiments. These findings indicated that Ad‐renalase‐administered rats had a lesser degree of CRS; regulation of blood pressure by degrading circulation norepinephrine may be at least in part mechanism for its protective effects.

Inflammation and oxidative stress plays a pivotal role in the progression of CKD. Our recent reports had shown that renalase protected HK2 cells against the cytotoxicity of H~2~O~2~ through suppressing oxidative stress and apoptosis and recombinant renalase protected against contrast‐induced nephropathy through anti‐oxidation and anti‐inflammation mechanism [12](#jcmm12813-bib-0012){ref-type="ref"}, [13](#jcmm12813-bib-0013){ref-type="ref"}. Other reports demonstrated that renalase‐knockout mice led to exacerbation of renal injury caused by acute cisplatin nephrotoxicity and ischemia/reperfusion damage through up‐regulation of pro‐inflammatory cytokines [15](#jcmm12813-bib-0015){ref-type="ref"}, [23](#jcmm12813-bib-0023){ref-type="ref"}. Herein, we found that renalase supplementation also inhibited inflammatory response in remnant kidney *via* down‐regualtion of pro‐inflammatory cytokines and NADPH oxidase components. Besides, we observed that Ad‐renalase treatment could not only reduce macrophage infiltration but also regulate change in macrophage M1/M2 phenotype during CKD progression. Renalase might attenuate renal inflammation *via* inhibiting pro‐inflammatory M1‐like macrophage polarization and promoting anti‐inflammation or antifibrosis M2‐like macrophage activation.

Evidence showed that renalase‐knockout mice exhibit mild LV hypertrophy and renalase polymorphisms are associated with cardiac hypertrophy in patients. Our results proved that renalase supplementation ameliorated cardiac fibrosis and cardiomyocytes hypertrophy, decreased LVPWd and LVEDP and restored cardiac diastolic function in CKD rats. SBP decline after renalase supplementation might be mainly accounted for improvement of cardiac function. Beside, this amelioration was accompanied by remarkably milder cardiomyocytes hypertrophy, reduced expression of pro‐fibrotic markers and inhibition of ERK‐1/2 activation.

It has been established that mitogen‐activated protein kinase (MAPK) activity plays an important role in cardiomyocytes hypertrophy and pressure‐overload induced cardiac remodelling. Takahashi *et al*. [42](#jcmm12813-bib-0042){ref-type="ref"} reported that the phosphorylation of ERK‐1/2, not p38 MAPK, was involved as an intracellular signalling pathway leading to cardiac hypertrophy in STNx rat model and blockade of ERK‐1/2 phosphorylation could prevent cardiac remodelling, which is consistent with our results. On the contrary, other studies [43](#jcmm12813-bib-0043){ref-type="ref"}, [44](#jcmm12813-bib-0044){ref-type="ref"} argued that a calcimimetic agent R‐568 or calcitriol increased the activation of ERK‐1/2 and improved cardiac fibrosis [43](#jcmm12813-bib-0043){ref-type="ref"}, [44](#jcmm12813-bib-0044){ref-type="ref"}. The opposite results may be caused by the different duration of experiment design and heterogeneity of animal operation. Interestingly, recent studies showed that phosphorylation of ERK may cause excess oxidative stress which could lead to cardiofibroblasts activation; and apocynin, an inhibitor of NADPH oxidase, attenuated cardiac fibrosis through inhibition ERK1/2 activation in STNx rats [45](#jcmm12813-bib-0045){ref-type="ref"}. We believed that suppressed phosphorylation of ERK‐1/2 after Ad‐renalase treatment was mediated *via* its indirect effects because previous studies revealed that renalase can activate ERK and p38 activation *in vitro*. Renalase treatment had changed the phenotype of STNx animals through decline of blood pressure and sympathetic hyperactivity, which might indirectly inhibit phosphorylation of ERK‐1/2.

Despite of the enzymatic activity of renalase, it has been suggested that renalase is also a cytokine which may mediate its cardio‐renal protective properties through its plasma membrane receptor. PMCA4b, as a recently identified receptor for renalase [22](#jcmm12813-bib-0022){ref-type="ref"}, is a calcium pump that participates in Ca^2+^‐dependent signalling. Previous reports demonstrated that PMCA4b transgenic mice exhibited improvement of LV hypertrophy following transverse aortic constriction or phenylephrine/Ang II infusion and PMCA4b overexpression inhibited cardiomyocyte hypertrophy *in vitro* [46](#jcmm12813-bib-0046){ref-type="ref"}. Supplementation of renalase may directly antagonize cardiac hypertrophy through activating extracellular PMCA4b on cardiomyocytes and related downstream signalling pathway in an endocrine manner.

There are some limitations of this study. First, the study duration is only 6 weeks which may be too short for CKD animals. Second, we could not conclude that renalase exerts its protective effects by lowering blood pressure or directly inhibiting fibrosis and hypertrophy of hearts because of lack of *in vitro* studies. Thus, kidney‐specific renalase‐knockout animal should be used in future study to determine the mechanism of renalase\'s protective effects in type 4 CRS.

In summary, renalase supplementation by systemic delivery of adenovirus‐renalase ameliorated both renal dysfunction and cardiac remodelling after subtotal nephrectomy in catecholamine‐lowering‐dependent/independent manners. The potential mechanism of its protective effects may be mediated by its anti‐inflammatory, anti‐oxidant function and inhibition of ERK1/2 pathway. Therefore, renalase is a crucial modulator of CRS progression and renalase supplementation may be a promising therapy for prevention and deterioration of CRS in CKD patients.
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**Figure S2** Evaluation of renalase expression efficacy by immunostaining.
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**Figure S3** Reprehensive echocardiography at week 6.
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